Katherine Stueland Sells 10,501 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $76.75, for a total value of $805,951.75. Following the transaction, the chief executive officer now owns 71,146 shares in the company, valued at $5,460,455.50. This represents a 12.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Price Performance

Shares of GeneDx stock traded down $2.27 on Wednesday, hitting $76.93. 1,156,038 shares of the company were exchanged, compared to its average volume of 458,372. GeneDx Holdings Corp. has a 1-year low of $1.76 and a 1-year high of $89.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -24.74 and a beta of 2.03. The company has a 50-day moving average price of $71.26 and a 200 day moving average price of $46.55.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. The business had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period last year, the company earned ($0.82) EPS. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the subject of several research reports. The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum raised their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average target price of $59.33.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. acquired a new position in GeneDx in the third quarter valued at approximately $301,000. Tidal Investments LLC purchased a new stake in GeneDx in the third quarter valued at $514,000. Barclays PLC lifted its stake in shares of GeneDx by 346.3% in the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of GeneDx by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company’s stock worth $16,030,000 after purchasing an additional 30,379 shares during the period. Finally, State Street Corp increased its position in shares of GeneDx by 18.3% during the 3rd quarter. State Street Corp now owns 314,914 shares of the company’s stock worth $13,365,000 after purchasing an additional 48,735 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.